Global Endometriosis Industry

NEW YORK, Jan. 21, 2019 /PRNewswire/ -- This report analyzes the worldwide markets for Endometriosis in US$ Million.



Read the full report: https://www.reportlinker.com/p04368326



The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.



Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.



The report profiles 38 companies including many key and niche players such as:

- AbbVie Inc.

- Astellas Pharma Inc.

- AstraZeneca Plc

- Bayer AG

- Debiopharm Group

- Evotec AG



Read the full report: https://www.reportlinker.com/p04368326



ENDOMETRIOSIS MCP-6

MARKET ANALYSIS, TRENDS, AND FORECASTS, JANUARY 2

CONTENTS



I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS



Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study



II. EXECUTIVE SUMMARY



1. INDUSTRY OVERVIEW



Endometriosis: An Introductory Prelude

Endometriosis Facts in a Nutshell

Poor Efficacy & Safety Profiles of Existing Drugs Lead to Unmet Medical Needs

Key Endometriosis Drugs on the Market

Table 1: Leading Endometriosis Drugs on the Market (2017E): Percentage Breakdown of Revenues for Depo-Provera, Lupron, Visanne, Zoladex and Others (includes corresponding Graph/Chart)

The Pipeline Review

Key Endometriosis Drugs in the Pipeline: 2017

Steady Growth Expected Over the Next Few Years

Emerging Treatment for Endometriosis & Endometrial Cancer

Global Awareness Campaigns and Efforts

Uptrend in Healthcare Expenditure Creates Substantial Opportunities

Table 2: Healthcare Spending as % of GDP by Geographic Region (2016) (includes corresponding Graph/Chart)

Table 3: Per Capita Healthcare Spending (in $) in Select Developed Countries for the Year 2016 (includes corresponding Graph/Chart)

Developed Regions Remain Primary Revenue Contributors

Table 4: Developed Regions Account for over 90% Share of World Endometriosis Drugs Market: Percentage Breakdown of Value Sales for Developed Regions and Developing Regions (2017E & 2022P) (includes corresponding Graph/Chart)

Developing Regions Exhibit Immense Growth Potential

Stable Economic Scenario to Augment Market Prospects

Table 5: World Real GDP Growth Rates in % (2016-2018P): Breakdown by Country/Region (includes corresponding Graph/Chart)



2. ENDOMETRIOSIS & ITS TREATMENT - AN OVERVIEW



Introduction

Occurrence of Endometriosis in Women

Causes and Symptoms

Causes

Estrogen Theory

Müllerianosis Theory

Retrograde Menstruation Theory

Coelomic Metaplasia Theory

Hereditary Factors

Environmental Factors

Dioxin Behavior in the Body

Birth Defects

Other Causes

Symptoms of Endometriosis

Reasons for Pain due to Endometriosis

Endometriosis and Infertility

Kinds of Endometriosis

Reproductive Area Endometriosis

Uterosacral/Presacral Nerve Endometriosis

Cul-de-Sac ("Pouch of Douglas") Endometriosis

Gastrointestinal Endometriosis

Pleural (lung/chest cavity/diaphragmatic) Endometriosis

Urinary Tract (kidneys, ureters, bladder and urethra) Endometriosis

Skin Endometriosis

Sciatic Endometriosis

Stages of Endometriosis

Diagnosis of Endometriosis

Major Diagnostic Techniques

Pelvic Exam

Laparoscopy

Other Diagnostic Procedures

A New Non-invasive Test for the Diagnosis of Endometriosis

Endometriosis Markers

Counseling of patients

Recurrence of Endometriosis

Endometriosis & Infertility

Miscarriage

Endometriosis & Thyroid Autoimmunity

Relationship between Endometriosis and Autoimmune Disease

Endometriosis & Cancer

Associations & Research Centers

The Endometriosis Association

Endometriosis Research Center



3. TREATMENT OF ENDOMETRIOSIS



Endometriosis & Available Treatment Options

Endometriosis Treatment Mechanisms: In a Nutshell



I. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)



II. Hormonal Therapy



Gonadotropin Releasing Hormone (Gnrh) Agonists

Select Major GnRH-Agonists for Endometriosis Treatment

Lupron, Zoladex and Synarel - The Major Drugs

AbbVie€™s Lupron® (Leuprorelin)

AstraZeneca€™s Zoladex® (Goserelin)

Pfizer€™s Synarel (Nafarelin Acetate)

Add-back Medication

Progestogens

Select Major Progestins for Endometriosis Treatment

Combined Oral Contraceptive Pill

Danazol and Other Suppressive Steroids

Chinese Herbs - More Effective than Danazol or Gestrinone

Aromatase Inhibitors



III. Non-hormonal Therapy



Anti-Angiogenic Agents

Selective COX-2 Inhibitors

TNF-Alpha Inhibitors



IV. Surgical Techniques



V. Complementary Therapies

Long-term Approach to Pain

Lifestyle Modifications

Chinese Herbs

Treatment for Endometriosis-related Infertility

Hormonal Treatment

Minimal to Mild Endometriosis

Moderate-Severe Endometriosis

Surgical Treatment

Minimal-Mild Endometriosis

Moderate-Severe Endometriosis

Treatment for Ovarian Endometriosis

Surgical Vs. Medicinal Interventions

Medicinal Interventions

Advantages

Disadvantages

Surgery

Advantages

Disadvantages

In-vitro Fertilization

Other Treatment



4. SELECT CLINICAL TRIALS/PRODUCT INNOVATIONS & APPROVALS



AbbVie and Neurocrine Bag US FDA Priority Review Clearance for Elagolix

AbbVie Announces Results from Replicate Phase 3 Extension Studies for Elagolix

Bayer Commences Enrolling Patients for Phase III Program to Study Vilaprisan€™s Efficacy in Treating Symptomatic UF

ObsEva to Commence Phase 2b EDELWEISS Clinical Trial of OBE2109

Repros Keeps Proellex® Development Program on Partial Clinical Hold of FDA

Aeterna Zentaris Halts Development of Zoptrex

Evotec and Bayer€™s Endometriosis Alliance Portfolio Advances into Phase I Clinical Development

ObsEva Commences Phase 3 Clinical Program to Evaluate OBE2

to Treat UF

Myovant Achieves Positive Phase 3 Study Results for Relugolix in Treating UF

Myovant Commences Phase 3 Program of Relugolix for Treating Endometriosis-Associated Pain

Repros Therapeutics€™ Achieves Positive Results from Proellex Phase II Study

ValiRx Bags European Patent for VAL201

Virexxa Receives FDA Clearance to Proceed to Phase II

OBE2109 by ObsEva Receives IND Clearance

Galena Biopharma Presents Phase 1/2a Data on Endometrial Cancer Immunotherapies

AbbVie and Neurocrine Report Positive Phase 3 Trial Data of Elagolix

ValiRx Plc to Begin Endometriosis Clinical Research with its VAL201

Aurobindo Pharma Receives FDA Approval to Market Tablets for Endometriosis Treatment

Lumenis to Introduce UltraPulse DUO CO2 laser system and FemTouch Solution

Bayer Launches Phase II Trials of vilaprisan for Endometriosis Treatment

Nippon Shinyaku Conducts Phase I Evaluation of NS 580 for Endometriosis Therapy

Teleflex to Showcase its Surgical Solutions for Endometriosis

ValiRx Plc Receives Patent Grant for VAL201



5. RECENT INDUSTRY ACTIVITY



AstraZeneca Bags Commercial Rights to Zoladex

Astellas Pharma to Acquire Ogeda

Roivant Establishes New Global Headquarters in Basel

Takeda and Roivant Partner to Form Myovant

Evotec-Bayer Collaboration Reaches Important Clinical Milestones for Endometriosis Therapy

ObsEva and Kissei Pharmaceutical Enter Into Collaboration Agreement for KLH-2109



6. FOCUS ON SELECT GLOBAL PLAYERS



AbbVie Inc. (USA)

Astellas Pharma Inc. (Japan)

AstraZeneca Plc (UK)

Bayer AG (Germany)

Debiopharm Group (Switzerland)

Evotec AG (Germany)

Kissei Pharmaceutical Co., Ltd. (Japan)

Neurocrine Biosciences, Inc. (USA)

ObsEva SA (Switzerland)

Pfizer, Inc. (USA)

Repros Therapeutics, Inc. (USA)

Roivant Sciences GmbH (Switzerland)

Takeda Pharmaceutical Company Limited (Japan)

ValiRx plc (UK)



7. GLOBAL MARKET PERSPECTIVE



Table 6: World Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 7: World Historic Review for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2

(includes corresponding Graph/Chart)

Table 8: World 14-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2017 and 2022 (includes corresponding Graph/Chart)



III. MARKET



1. THE UNITED STATES



A.Market Analysis

Largest Market for Endometriosis Drugs

Endometriosis Associations Increase Awareness

Newer Diagnostic Methods Yet to Expand Across the Country

Key Endometriosis Drugs on the Market

Product Launches/Clinical Trials

Strategic Corporate Developments

Key Players

B.Market Analytics

Table 9: The US Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 10: The US Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)



2. CANADA



A.Market Analysis

Product Launch

Key Players

B.Market Analytics

Table 11: Canadian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 12: Canadian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)



3. JAPAN



A.Market Analysis

Clinical Trial

Key Players

B.Market Analytics

Table 13: Japanese Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 14: Japanese Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)



4. EUROPE



Market Analysis

Table 15: European Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 16: European Historic Review for Endometriosis Drugs by Geographic Region/ Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2

through 2014 (includes corresponding Graph/Chart)

Table 17: European 14-Year Perspective for Endometriosis Drugs by Geographic Region/ Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of European Markets for Years 2009, 2017 and 2

(includes corresponding Graph/Chart)



4a. FRANCE

A.Market Analysis

Programmes to Maintain Endometriosis Database

B.Market Analytics

Table 18: French Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 19: French Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)



4b. GERMANY

A.Market Analysis

Clinical Trials

Strategic Corporate Development

Key Players

B.Market Analytics

Table 20: German Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 21: German Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)



4c. ITALY

Market Analysis

Table 22: Italian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 23: Italian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)



4d. THE UNITED KINGDOM

A.Market Analysis

Product Launches/Clinical Trials

Key Players

B.Market Analytics

Table 24: The UK Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 25: The UK Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)



4e. SPAIN

Market Analysis

Table 26: Spanish Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 27: Spanish Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)



4f. REST OF EUROPE

A.Market Analysis

Product Launches/Clinical Trials

Strategic Corporate Developments

Key Players

B.Market Analytics

Table 28: Rest of Europe Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 29: Rest of Europe Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)



5. ASIA-PACIFIC



A.Market Analysis

The Rapidly Growing Market

Endometriosis Therapeutics in Australia

B.Market Analytics

Table 30: Asia-Pacific Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 31: Asia-Pacific Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)



6. REST OF WORLD



A.Market Analysis

Product Launch

B.Market Analytics

Table 32: Rest of World Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 33: Rest of World Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)



IV. COMPETITIVE LANDSCAPE



Total Companies Profiled: 38 (including Divisions/Subsidiaries - 40) The United States (11) Canada (3) Japan (6) Europe (15) - France (1) - Germany (3) - The United Kingdom (2) - Rest of Europe (9) Asia-Pacific (Excluding Japan) (3) Middle East (1) Latin America (1)

Read the full report: https://www.reportlinker.com/p04368326



About Reportlinker

ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.



__________________________

Contact Clare: clare@reportlinker.com

US: (339)-368-6001

Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/global-endometriosis-industry-300781472.html

SOURCE Reportlinker